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Abstract
The clinical features in psoriatic arthritis straddle the divide
between rheumatoid arthritis on the one hand and spondylo-
arthropathy on the other. The paper by Kruithof and colleagues
compares synovial immunohistologic features and clearly identifies
psoriatic arthritis as being a member of the spondyloarthropathy
family.
The excellent article by Kruithof and colleagues stimulates
many questions while carefully dissecting differentiating
features in synovial histopathology that characterize
rheumatoid arthritis (RA) and spondyloarthropathy (SpA), in
particular psoriatic arthritis (PsA) [1]. Using a semi-
quantitative scoring system, the authors identified a number
of features characteristic of RA synovium, including the lining
layer thickness, CD83+ dendritic cells, positive staining for
intracellular citrullinated proteins (44%) and positive staining
for MHC/HC gp-39 peptide complexes (46%). In the SpA
group as a whole and in the PsA subgroup alone, increased
vascularity and neutrophil numbers distinguished from RA.
CD163+ macrophages were also increased in SpA.
Interestingly, no significant differences were seen between
oligoarticular PsA versus polyarticular PsA. The authors
conclude that the synovitis in PsA, both oligoarticular and
polyarticular, resembles SpA more than RA.
These observations have a number of important implications.
First, although this has been disputed [2], it may be possible
to diagnose RA based on the positive staining as already
stated. In Kruithof and colleagues’ study, positive staining for
intracellular citrullinated proteins and positive staining for
MHC/HC gp-39 peptide complexes were seen only in RA,
although each were present in <50%. Second, the synovitis
in PsA shows similar features to other SpA patients, both
ankylosing spondylitis and undifferentiated SpA.
Previous studies have compared PsA with RA [3], although
Kruithof and colleagues’ study is the first to include other
SpA patients in the comparison. In the previous study [3], an
increase in vessel number was also a distinguishing feature
from RA, as were lower macrophage numbers and a
reduction in E-selectin expression. Kruithof and colleagues
were unable to confirm these findings, which have been
confirmed by others [4], but this may relate to issues of
patient selection and to methods of quantification of cellular
infiltration (semi-quantitative versus quantitative). The
interesting additional observation of an increase in neutrophil
infiltration in PsA is consistent both with the well-described
neutrophil infiltration seen in psoriasis (Ps) skin [5] and with
the observation of Flt-1-positive neutrophils in PsA synovium
[6]. It is clear that the role of the neutrophil in both Ps and
PsA requires further study.
The finding that the synovial immunohistologic features of
oligoarticular-type PsA and polyarticular-type PsA are not
different and that they both are more like other SpA patients
than RA patients answers an important question: is
polyarticular PsA really RA in disguise but with coincidental
Ps? Indeed, McGonagle and colleagues have proposed a
new classification for PsA based on entheseal involvement
where patients with predominant synovitis and Ps would be
grouped with RA [7]. The results in Kruithof and colleagues’
paper would suggest that this proposed classification is not
appropriate.
The subject of classification of PsA has been controversial,
and many classifications have been proposed since the
original Moll and Wright classification in 1974. The
Classification of Psoriatic Arthritis initiative led by Philip
Helliwell will be reporting later this year on a multicentre
prospective case–control study to determine classification
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criteria in a large number of unselected patients. While the
results of this study are eagerly awaited, it is possible that
dividing patients up by the number of joints involved has little
relevance other than identifying those with a poor prognosis.
Previous studies have identified both the number of inflamed
joints and an elevated erythrocyte sedimentation rate to be
associated with poor outcome [8]. In addition, classification
criteria in established PsA appear to be confounded by the
effects of therapy, with 49% of PsA patients who were
classified as polyarticular at presentation being reclassified
as oligoarticular after 2 years [9]. It may thus be that attempts
to classify PsA may have little clinical utility.
PsA belongs to the SpA family, and the focus should be on
trying to identify features, perhaps common to the target
tissues (skin, synovium and enthesis), which are specific for
the disease. To date, efforts have focused on detailed tissue
analysis and on studies of T-cell specificity but have largely
failed to identify either disease-specific immunohistologic
features (cell markers/cytokine expression) [1,3,10] or
evidence of T-cell antigen drive [11]. Future studies using
detailed differential analysis of gene (genomics) expression or
protein (proteomics) expression may be more informative.
Finally, while Kruithof and colleagues’ results indicate that
PsA belongs to the SpA family, this does not mean that all
SpA is the same. There are clinical, genetic and radiological
features that are associated with PsA and that together
suggest a unique clinical entity. At the very least, the joint
disease in PsA is modified by the presence of Ps to produce
a form of SpA with easily distinguished clinical features.
Again, this supports the final conclusion by Kruithof and
colleagues that more detailed studies are required “to unravel
pathogenetic and phenotypic differences and similarities”.
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